Arce Carlota, Lobo Inês, Rodrigues Alexandra, Machado Susana, Nogueira Miguel, Linhares Paulo
Medicine Faculty of Porto University, Alameda Prof. Hernâni Monteiro 4200-319 Porto, Portugal.
Dermatology Department, Centro Hospitalar e Universitário de Santo António, Largo do Prof. Abel Salazar 4099-001 Porto, Portugal.
Eur J Dermatol. 2025 Jun 1;35(3):218-223. doi: 10.1684/ejd.2025.4903.
Hidradenitis suppurativa (HS) is a recurrent chronic inflammatory disease marked by painful lesions in intertriginous regions. Recent studies highlight neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), monocyte-to-lymphocyte ratio (MLR), and C-reactive protein (CRP) as systemic inflammation markers correlated with disease severity. This study aimed to analyse changes in inflammatory parameters in HS patients pre- and post-16-week adalimumab treatment. We sought to understand if changes in these parameters have any correlation with response to treatment. A retrospective cohort of 44 adalimumab-treated HS patients was used to evaluate laboratory (NLR, PLR, MLR, CRP) and clinical (DLQI, IHS4, IHS4-55 and PI-NRS) parameters. Data, collected between 2019 and 2023, underwent statistical analysis including t-tests, Wilcoxon signed-rank tests and Pearson correlation tests, comparing pre- and post-treatment values. Adalimumab treatment led to a significant improvement in HS inflammatory markers. Clinical scores, including DLQI, (p<0.0001), IHS4 (p<0.0001) and PI-NRS (p<0.0001), showed significant reduction post-treatment. Analytical variables, NLR (p=0.02), PLR (p=0.02), CRP median (p=0.01), and MLR median (p=0.027), also exhibited significant decreases. In most patients, IHS4-55 scores did not show a 55% reduction. No significant correlation was found between baseline clinical scores and inflammatory parameters. All systemic inflammation-based biomarkers were significantly reduced after starting adalimumab. The clinical scores of DLQI, IHS4 and PI-NRS were also significantly decreased. Contrarily, in most patients, the IHS4-55 score did not show a 55% reduction. This suggests that haematological markers of inflammation may predict response to treatment with adalimumab.
化脓性汗腺炎（HS）是一种复发性慢性炎症性疾病，其特征为褶皱部位出现疼痛性病变。最近的研究强调中性粒细胞与淋巴细胞比值（NLR）、血小板与淋巴细胞比值（PLR）、单核细胞与淋巴细胞比值（MLR）以及C反应蛋白（CRP）作为与疾病严重程度相关的全身炎症标志物。本研究旨在分析HS患者在接受16周阿达木单抗治疗前后炎症参数的变化。我们试图了解这些参数的变化是否与治疗反应有任何相关性。一项回顾性队列研究纳入了44例接受阿达木单抗治疗的HS患者，以评估实验室参数（NLR、PLR、MLR、CRP）和临床参数（DLQI、IHS4、IHS4 - 55和PI - NRS）。收集了2019年至2023年期间的数据，并进行了统计分析，包括t检验、Wilcoxon符号秩检验和Pearson相关检验，比较治疗前后的值。阿达木单抗治疗使HS炎症标志物有显著改善。包括DLQI（p<0.0001）、IHS4（p<0.0001）和PI - NRS（p<0.0001）在内的临床评分在治疗后显著降低。分析变量NLR（p = 0.02）、PLR（p = 0.02）、CRP中位数（p = 0.01）和MLR中位数（p = 0.027）也呈现出显著下降。在大多数患者中，IHS4 - 55评分未显示降低55%。在基线临床评分与炎症参数之间未发现显著相关性。开始使用阿达木单抗后，所有基于全身炎症的生物标志物均显著降低。DLQI、IHS4和PI - NRS的临床评分也显著下降。相反，在大多数患者中，IHS4 - 55评分未显示降低55%。这表明炎症的血液学标志物可能预测阿达木单抗治疗的反应。
